Avivagen Announces Sales in Thailand
25 Junho 2013 - 9:00AM
Access Wire
OTTAWA, ONTARIO, June 25, 2013 -
Avivagen Inc. (TSXV:VIV), a wellness company
developing and delivering products that support and enhance the
health and quality of life for animals and the people who care for
them, announces its first commercial sale of OxC-beta for
livestock, in Thailand.
Avivagen announces
that OxC-beta is now commercially available in the Kingdom of
Thailand and receipt of payment for its first commercial order.
Avivagen believes that OxC-beta will be a valuable tool for
producers in the aquaculture and livestock industries of that
country and is pleased to make its novel and proprietary product
available. Thailand has large aquaculture, poultry and pork
industries that collectively produce approximately 3.4 million
metric tons of such meats each year.
Dr. Janusz Daroszewski, Director,
Product Development and Quality Assurance of Avivagen commented on
the first sale of OxC-beta into Thailand. "We're pleased to make
our exciting product available for producers across Thailand. As
parties working with OxC-beta have discovered, it can be a valuable
tool for enhancing and maintaining livestock health. We look
forward to realizing the full sales potential of OxC-beta in
Thailand and across Asia."
Cameron Groome, CEO and
President of Avivagen also commented "We're
delighted to have gained market access and obtained our first
commercial order for the important market of Thailand. Today's news
serves as validation of our strategy to secure present-day sales of
OxC-beta by way of countries and market sectors that are welcoming
to novel natural-product solutions to livestock health
concerns."
Prior studies of
OxC-beta have shown that parts-per-million dosing is associated
with enhanced innate immunity and improvements to outcome measures
such as Average Daily Gain, Feed Conversion Rates and Final Weight.
Similar results have been observed across multiple food animal
species, including fish, chickens, pigs and cattle. Avivagen is
continuing work towards identifying optimal protocols for use of
OxC-beta in several categories of food animals.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life
sciences company trading on the TSX Venture Exchange under the
ticker symbol "VIV". The Company's goal is to
develop and deliver scientifically-proven solutions that can truly
benefit companion and food animals by taking advantage of natural
mechanisms for maintaining optimal health. Avivagen's targeted
markets include Pet Wellness and Livestock Productivity.
The company has sites located in
partnership facilities of the National Research Council of Canada
(NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward
Island.
More information can be found at
www.avivagen.com.
About
OxC-beta
Avivagen's
proprietary and patent-protected technology supports the body's own
systems to maintain and enhance health, particularly by supporting
immune function. Avivagen's commercial-stage application of its
technology is Fully-Oxidized beta-Carotene (OxC-beta).
OxC-beta compounds occur naturally as
carotenoid oxidation products in vegetation, but in minute amounts.
They have been developed to support the health of companion animals
and for use in the global food animal market.
Research results indicate OxC-beta helps
support immune function, which can result in meaningful overall
health benefits. In pets, benefits are seen in overall vitality and
energy, skin, coat and gastrointestinal wellness. Benefits observed
in food animals have included healthier growth, better utilization
of feed and decreased mortality. In food animals, it is intended
that use of OxC-beta avoids the feeding of antibiotics.
The commercial
products of Avivagen are Oximunol(TM) Chewables and OxC-beta for
livestock.
About Oximunol(TM)
Chewables - "Optimized Health in a Chewable Tablet"
Oximunol(TM) Chewables is a
scientifically-formulated chewable tablet
that contains Avivagen's proprietary, patented active ingredient
OxC-beta. Oximunol(TM) Chewables are currently available for dogs
of all ages in the United States, working with a dog's own immune
system to optimize overall health and well-being.
About OxC-beta for Livestock
OxC-beta for Livestock is
available as a 10% pre-mix sold in 1.0 or 5.0 Kg
quantities for parts-per-million addition to animal feeds, in
accordance with producer-developed protocols. In past studies,
OxC-beta has been shown to have health and growth benefits in
species such as fish, chicken, pigs and cattle. OxC-beta for
livestock is currently available for commercial sale in the Kingdom
of Thailand.
Forward
Looking Statements
This
news release includes certain forward-looking statements that are
based upon current expectations, which involve risks and
uncertainties associated with the business of Avivagen Inc. and the
environment in which the business operates. Any statements
contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the
expressions "will", "anticipate", "believe", "plan", "estimate",
"expect", "intend", and similar expressions. The forward-looking
statements reflect the current expectations of Avivagen Inc.
regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from
current expectations. Avivagen assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those reflected in the forward-looking
statements.
Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
For more
information:
Avivagen Inc.
Cameron Groome
CEO & President
Phone: 613-949-8164
c.groome@avivagen.com
Avivagen (TSXV:VIV)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Avivagen (TSXV:VIV)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024